Kiora Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Balance Sheet Information (Tables)

Balance Sheet Information (Tables)

9 Months Ended

Sep. 30, 2022

Balance Sheet Information

Schedule of of cash and cash equivalents and restricted cash


		September 30, 2022
		(unaudited)			December 31, 2021
Cash and Cash Equivalents		$	4,801,616		$	7,854,690
Restricted Cash, Non-current			49,037			45,000
Total Cash, Cash Equivalents and Restricted Cash		$	4,850,653		$	7,899,690

Schedule of prepaid expenses and other current assets


		September 30, 2022
		(unaudited)			December 31, 2021
Prepaid Insurance		$	97,617		$	130,765
Prepaid Research and Development			36,760			319,208
Other			125,628			156,547
Total Prepaid Expenses and Other Current Assets		$	260,005		$	606,520

Schedule of accrued expenses


		September 30, 2022
		(unaudited)			December 31, 2021
Executive Severance		$	666,784		$	200,605
Payroll and Benefits			550,133			737,365
Professional Fees			442,605			194,425
Clinical Trials			124,858			168,785
Other			15,630			28,961
Total Accrued Expenses		$	1,800,010		$	1,330,141